Department of Orthopaedic Surgery, Inje University College of Medicine, Seoul Paik Hospital, Seoul, South Korea.
Department of Orthopaedic Surgery, Center for Metabolism and Obesity Research Johns Hopkins University School of Medicine, Baltimore, MD.
J Arthroplasty. 2019 Jan;34(1):169-174.e1. doi: 10.1016/j.arth.2018.09.006. Epub 2018 Sep 22.
Although alcohol is a leading risk factor for osteonecrosis of the femoral head (ONFH) and its prevalence reportedly ranges from 20% to 45%, there are no unified classification criteria for this subpopulation. In 2015, Association Research Circulation Osseous decided to develop classification criteria for alcohol-associated ONFH.
In June of 2017, Association Research Circulation Osseous formed a task force to conduct a Delphi survey. The task force invited 28 experts in osteonecrosis/bone circulation from 8 countries. Each round of the Delphi survey included questionnaires, analysis of replies, and feedback reports to the panel. After 3 rounds of the survey, consensus was reached on the classification criteria. The response rates for the 3 Delphi rounds were 100% (round 1), 96% (round 2), and 100% (round 3).
The consensus on the classification criteria of alcohol-associated ONFH included the following: (1) patients should have a history of alcohol intake >400 mL/wk (320 g/wk, any type of alcoholic beverage) of pure ethanol for more than 6 months; (2) ONFH should be diagnosed within 1 year after alcohol intake of this dose; and (3) patients should not have other risk factor(s).
ARCO-established classification criteria to standardize clinical studies concerning AA-ONFH.
尽管酒精是股骨头坏死(ONFH)的主要危险因素,其患病率据报道在 20%至 45%之间,但针对该亚群尚无统一的分类标准。2015 年,国际骨骼研究协会决定制定与酒精相关的 ONFH 的分类标准。
2017 年 6 月,国际骨骼研究协会成立了一个工作组,进行了一项 Delphi 调查。该工作组邀请了来自 8 个国家的 28 名骨坏死/血液循环专家。Delphi 调查的每一轮都包括问卷、回复分析和向小组反馈报告。经过三轮调查,达成了分类标准的共识。三轮 Delphi 调查的回复率均为 100%(第一轮)、96%(第二轮)和 100%(第三轮)。
关于酒精相关性 ONFH 的分类标准的共识包括以下内容:(1)患者应具有超过 6 个月、每周摄入>400ml(320g,任何类型的酒精饮料)纯乙醇的饮酒史;(2)在摄入此剂量的酒精后 1 年内应诊断为 ONFH;和(3)患者不应有其他危险因素。
ARCO 制定了分类标准,以规范有关 AA-ONFH 的临床研究。